国际眼科纵览

• 综述 • 上一篇    下一篇

增生性糖尿病视网膜病变围手术期抗VEGF药物使用时机的选择

延艳妮  魏文斌  周金琼   

  1. 100730首都医科大学附属北京同仁医院北京同仁眼科中心 眼科学与视觉科学北京市重点实验室
  • 收稿日期:2014-08-18 出版日期:2015-10-22 发布日期:2015-10-27
  • 通讯作者: 魏文斌 E-mail:tr_weiwenbin@163.com

The using timing  of anti-vascular endothelial growth factor  at perioperative period for proliferative diabetic retinopathy

YAN Yan-ni, WEI Wen-bin, ZHOU Jin-qiong.   

  1. Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Key Laboratory of Ophthalmology and Visual Sciences, Beijing 100730, China
  • Received:2014-08-18 Online:2015-10-22 Published:2015-10-27
  • Contact: WEI Wen-bin E-mail:tr_weiwenbin@163.com

摘要:

增生性糖尿病视网膜病变(proliferative diabetic retinopathy,PDR)是主要致盲性眼病之一。近几年大量基础和临床研究表明将抗血管内皮生长因子(vascular endothelial grow factor,VEGF)药物玻璃体腔注射和全视网膜光凝或玻璃体视网膜手术联合应用治疗PDR可取得良好效果,有效减少手术并发症。但抗VEGF药物使用时机的选择临床应用中一直缺乏定论。术前注药可有效降低手术难度,术中用药减少手术次数。因此,手术医生应根据患者情况选择合适注药时机,以使患者获得最大利益.(国际眼科纵览,2015,39:333.336)

Abstract:

Proliferative diabetic retinopathy is a major cause of blindness. Recently a large number of basic and clinical studies have shown that the treatments of intravitreal anti-vascular endothelial grow factor(VEGF) injection combined with panretinal photocoagulation or vitrectomy can achieve a good effect and reduce surgical complications. But using timing of anti-VEGF is an issue in clinic. A preoperative intravitreal injection can make the operation more easy, while intraoperative injection reduces the  operation frequency. Surgeons should choose appropriate injection timing according to the patient situation to greatly benefit patients.(Int Rev Ophthalmol,2015,39:333.336)